The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia
Open accessAbstract
BACKGROUND: In a previous open-label study of hydroxyurea therapy, the synthesis of fetal hemoglobin increased in most patients with sickle cell anemia, with only mild myelotoxicity. By inhibiting sickling, increased levels of fetal hemoglobin might decrease the frequency of painful crises. METHODS: In a double-blind, randomized clinical trial, we tested the efficacy of hydroxyurea in reducing the frequency of painful crises in adults with a history of three or more such crises per year. The trial was stopped after a mean follow-up of 21 months. RESULTS: Among 148 men and 151 women studied at 21 clinics, the 152 patients assigned to hydroxyurea treatment had lower annual rates of crises than the 147 patients given placebo (median, 2.5 vs. 4.5 crises per year, P < 0.001). The median times to the first crisis (3.0 vs. 1.5 months, P = 0.01) and the second crisis (8.8 vs. 4.6 months, P < 0.001) were longer with hydroxyurea treatment. Fewer patients assigned to hydroxyurea had chest syndrome (25 vs. 51, P < 0.001), and fewer underwent transfusions (48 vs. 73, P = 0.001). At the end of the study, the doses of hydroxyurea ranged from 0 to 35 mg per kilogram of body weight per day. Treatment with hydroxyurea did not cause any important adverse effects. CONCLUSIONS: Hydroxyurea therapy can ameliorate the clinical course of sickle cell anemia in some adults with three or more painful crises per year. Maximal tolerated doses of hydroxyurea may not be necessary to achieve a therapeutic effect. The beneficial effects of hydroxyurea do not become manifest for several months, and its use must be carefully monitored. The long-term safety of hydroxyurea in patients with sickle cell anemia is uncertain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“inhibition of HbS polymerization with hydroxyurea reduces the incidence of ACS (205).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [205]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By inducing increased levels of HbF through mechanisms that include suppressing erythropoiesis, hydroxyurea was first associated with reduction of morbidity and mortality in adults.81,82”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [81]
Experimental — accuracy not yet measuredIn the citing paper
“Administration of hydroxyurea has been shown to induce expression of HbF, which interferes with the polymerization of HbS (33).”
From Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia (2017) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An introduction to probability theory and its applications
(1958) · Journal of the Franklin Institute · doi:10.1016/0016-0032(58)90688-4 · Cited by 29,621
Draper, N. R., & Smith, H. (2005) · Technometrics · doi:10.1198/tech.2005.s303 · Cited by 17,993
Practical Nonparametric Statistics (2nd ed).
Groeneveld, R. A., & Conover, W. J. (1981) · Journal of the American Statistical Association · doi:10.2307/2287607 · Cited by 1,869
Pain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
Platt, O., Orkin, S. H., Dover, G., Beardsley, G. P., Miller, B. A., & Nathan, D. G. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111464 · Cited by 532
Self-citationHydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments]
Charache, S., Dover, G. J., Moore, R. D., Eckert, S. V., Ballas, S., Koshy, M., Milner, P., Orringer, E., Phillips, G., & Platt, O. (1992) · Blood · doi:10.1182/blood.v79.10.2555.2555 · Cited by 438
Self-citation5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons.
DeSimone, J., Heller, P., Hall, L., & Zwiers, D. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.14.4428 · Cited by 384
Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication
Lori, F., Malykh, A., Cara, A., Sun, D. K., Weinstein, J. N., Lisziewicz, J., & Gallo, R. C. (1994) · Science · doi:10.1126/science.7973634 · Cited by 317
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments]
Charache, S., Dover, G. J., Moore, R. D., et al. (1992) · Blood · doi:10.1182/blood.v79.10.2555.bloodjournal79102555 · Cited by 301
Self-citationDover, G. J., Brusilow, S. W., & Charache, S. (1994) · Blood · doi:10.1182/blood.v84.1.339.bloodjournal841339 · Cited by 229
Self-citation
Research works printed but not linked: 10
- Dover GJ, 1994, Blood, 84, 339, 10.1182/blood.V84.1.339.339 · DOI
- 1994, Blood, 84, 404a
- Kalbfleisch JD, Prentice RL. The stastistical analysis of failure time data. New York: John Wiley, 1980:1-20, 70-142.
- Ferm VH, 1966, Arch Pathol, 81, 174
- Weichselbaum RR, Hallahan DE, Chen GTY. Biological and physical basis to radiation oncology. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer medicine. 3rd ed. Vol. 1. Philadelphia: Lea & Febiger, 1993:539-66.
- Chemotherapeutic agents. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer medicine. 3rd ed. Vol. 1. Philadelphia: Lea & Febiger, 1993:698-814.
- Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, berlin NI, eds. Polycythemia vera and the myeloproliferative disorders. Philadelphia: W.B. Saunders, 1995:166-94.
- Fruchtman SM, 1994, Blood, 84, 518a
- Boivin P, 1993, Nouv Rev Fr Hematol, 35, 491
- Triadou P, 1994, Nouv Rev Fr Hematol, 36, 367
Cited by
Sorted by citations
Items 601–700 of 1,004
Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease
Li, Q., Henry, E. R., Hofrichter, J., Smith, J. F., Cellmer, T., Dunkelberger, E. B., Metaferia, B. B., Jones-Straehle, S., Boutom, S., Christoph, G. W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619054114 · Cited by 47
Wonkam, A., Mnika, K., Bitoungui, V. J. N., Chemegni, B. C., Chimusa, E. R., Dandara, C., & Kengne, A. P. (2017) · British Journal of Haematology · doi:10.1111/bjh.15011 · Cited by 48
“Descriptive statistics was performed using STATA, version 14.0.370 (StataCorp, College Station, TX, USA).”
ResultInfluentialBone Marrow Transplantation for Non-Malignant Disease
Sullivan, K. M., Parkman, R., & Walters, M. C. (2000) · Hematology · doi:10.1182/asheducation-2000.1.319 · Cited by 50
The Influence of Renal Function on Hydroxyurea Pharmacokinetics in Adults With Sickle Cell Disease
Yan, J., Ataga, K. I., Kaul, S., Olson, J. S., Grasela, D. M., Gothelf, S., Kutlar, A., & Orringer, E. P. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004273526 · Cited by 47
Adherent leukocytes capture sickle erythrocytes in an in vitro flow model of vaso‐occlusion
Finnegan, E. M., Turhan, A., Golan, D. E., & Barabino, G. A. (2006) · American Journal of Hematology · doi:10.1002/ajh.20819 · Cited by 47
Haynes, J., Baliga, B. S., Obiako, B. O., Ofori-Acquah, S. F., & Pace, B. S. (2004) · Blood · doi:10.1182/blood-2003-08-2969 · Cited by 47
Marlowe, K. F., & Chicella, M. F. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.7.484.33675 · Cited by 47
Pharmacokinetics of Hydroxyurea in Patients Infected with Human Immunodeficiency Virus Type I
Villani, P., Maserati, R., Regazzi, M. B., Giacchino, R., & Lori, F. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04176.x · Cited by 47
Anaesthetic care for sickle cell disease
Frietsch, T., Ewen, I., & Waschke, K. F. (2001) · European Journal of Anaesthesiology · doi:10.1046/j.0265-0215.2000.00804.x · Cited by 47
Swank, R. A., & Stamatoyannopoulos, G. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80095-6 · Cited by 46
Efficacy of Hydroxyurea in Providing Transfusion Independence in β-Thalassemia
Ansari, S. H., Shamsi, T. S., Ashraf, M., Perveen, K., Farzana, T., Bohray, M., Erum, S., & Mehboob, T. (2011) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e31821b0770 · Cited by 51
Outcome of holistic care in Nigerian patients with sickle cell anaemia
Akinyanju, O. O., Otaigbe, A. I., & Ibidapo, M. O. (2005) · Clinical & Laboratory Haematology · doi:10.1111/j.1365-2257.2005.00683.x · Cited by 46
Advances in clinical research in sickle cell disease
Hagar, W., & Vichinsky, E. P. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07097.x · Cited by 46
Paule, I., Sassi, H., Habibi, A., Pham, K. P., Bachir, D., Galactéros, F., Girard, P., Lesne-Hulin, A., & Tod, M. M. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-30 · Cited by 47
Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex
Gabbianelli, M., Testa, U., Morsilli, O., Pelosi, E., Saulle, E., Petrucci, E., Castelli, G., Giovinazzi, S., Mariani, G., Fiori, M. E., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.018259 · Cited by 46
Field, J. J., Majerus, E. M., Gordeuk, V. R., Gowhari, M., Hoppe, C. C., Heeney, M. M., Achebe, M., George, A., Chu, H. C., Sheehan, B., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009613 · Cited by 46
Immune mechanisms involved in sickle cell disease pathogenesis: current knowledge and perspectives
de Azevedo, J. T. C., & Malmegrim, K. C. R. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.04.012 · Cited by 46
Anie, K. A., Telfair, J., & The Sickle Cell Disease Transition Study Group (2005) · International Journal of Adolescent Medicine and Health · doi:10.1515/ijamh.2005.17.2.169 · Cited by 46
Abboud, M. R., Taylor, E. C., Habib, D. M., Dantzler‐Johnson, T., Jackson, S. M., Xu, F., Laver, J. H., & Ballas, S. K. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02358.x · Cited by 46
DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea
Friedrisch, J. R., Prá, D., Maluf, S. W., Bittar, C. M., Mergener, M., Pollo, T. A., Kayser, M. L., da Silva, M. A. L., Henriques, J. A. P., & Silla, L. M. D. R. (2007) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2007.09.005 · Cited by 46
Unusual causes of abdominal pain: sickle cell anemia
Ahmed, S., Shahid, R. K., & Russo, L. A. (2005) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2004.11.007 · Cited by 46
Opportunities to improve outcomes in sickle cell disease.
Mehta, S. R., Afenyi‐Annan, A., Byrns, P. J., & Lottenberg, R. (2006) · PubMed · Cited by 46
Mechanisms of pain in sickle cell disease
Takaoka, K., Cyril, A. C., Jinesh, S., & Radhakrishnan, R. (2020) · British Journal of Pain · doi:10.1177/2049463720920682 · Cited by 50
Structural Racism and Impact on Sickle Cell Disease
Smith, W. R., Valrie, C. R., & Sisler, I. Y. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.08.008 · Cited by 45
Nickel, R. S., Osunkwo, I., Garrett, A. P., Robertson, J. M., Archer, D. R., Promislow, D., Horan, J., Hendrickson, J. E., & Kean, L. S. (2015) · British Journal of Haematology · doi:10.1111/bjh.13326 · Cited by 45
“Hydroxycrabamide has many proven clinical benefits for patients with SCD (Charache et al , 1995; Wang et al , 2011), however some clinicians still have reservations about recommending HC therapy and many patients refuse HC.”
BackgroundJones, K. M., Niaz, M. S., Brooks, C. M., Roberson, S. I., Aguinaga, M. D. P., Hills, E. R., Rice, V. M., Bourne, P., Bruce, D. F., & Archibong, A. E. (2009) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph6031124 · Cited by 48
Pittman, D. D., Hines, P. C., Beidler, D. R., Rybin, D. V., Frelinger, A. L., Michelson, A. D., Liu, K., Gao, X., White, J. U., Zaidi, A. U., et al. (2020) · Blood · doi:10.1182/blood.2020006020 · Cited by 45
Inflammatory targets of therapy in sickle cell disease
Owusu-Ansah, A. T., Ihunnah, C. A., Walker, A. L., & Ofori-Acquah, S. F. (2015) · Translational research · doi:10.1016/j.trsl.2015.07.001 · Cited by 46
Tang, D. C., Zhu, J., Liu, W., Chin, K., Sun, J., Chen, L., Hanover, J. A., & Rodgers, G. P. (2005) · Blood · doi:10.1182/blood-2003-10-3458 · Cited by 45
Pyridyl Derivatives of Benzaldehyde as Potential Antisickling Agents
Nnamani, I., Joshi, G. S., Danso-Danquah, R. E., Abdulmalik, O. Y., Asakura, T., Abraham, D. J., & Safo, M. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890165 · Cited by 45
Olnes, M. J., Chi, A., Haney, C., May, R., Minniti, C. P., Taylor, J. G., & Kato, G. J. (2009) · American Journal of Hematology · doi:10.1002/ajh.21446 · Cited by 45
Defining stroke risk in children with sickle cell anaemia
Hoppe, C. C. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05310.x · Cited by 45
Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease
Green, N., & Barral, S. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22754 · Cited by 44
Coping and health service utilisation in a UK study of paediatric sickle cell pain
Anie, K. A. (2002) · Archives of Disease in Childhood · doi:10.1136/adc.86.5.325 · Cited by 45
Molecular characterization of β-thalassemia genes in an Argentine population
Roldán, A., Gutiérrez, M., Cygler, A. M., Bonduel, M. M., Sciuccati, G. B., & Torres, A. F. (1997) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199703)54:3
Nonideality and the Nucleation of Sickle Hemoglobin
Mv, I., Jasuja, R., Kwong, S., Briehl, R. W., & Ferrone, F. A. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76355-7 · Cited by 45
Sickle Cell Anemia — Basic Research Reaches the Clinic
Schechter, A. N., & Rodgers, G. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322010 · Cited by 45
Lebensburger, J. D., Sidonio, R. F., DeBaun, M. R., Safford, M. M., Howard, T. H., & Scarinci, I. C. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24486 · Cited by 44
PATHOPHISIOLOGY OF SICKLE CELL DISEASE AND NEW DRUGS FOR THE TREATMENT
Franceschi, L. D. (2009) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2009.024 · Cited by 44
Shearstone, J. R., Golonzhka, O., Chonkar, A., Tamang, D., van Duzer, J. H., Jones, S. S., & Jarpe, M. B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153767 · Cited by 43
“Moreover, induction of HbF by hydroxyurea in SCD patients is directly proportional to improved clinical response [4, 5].”
BackgroundInfluentialMorgan, R. A., Unti, M. J., Aleshe, B., Brown, D., Osborne, K. S., Koziol, C., Ayoub, P. G., Smith, O. B., O’Brien, R., Tam, C., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.020 · Cited by 46
Rees, D. C., Kılınç, Y., Ünal, S., Dampier, C., Pace, B. S., Kaya, B., Trompeter, S., Odame, I., Mahlangu, J. N., Ünal, Ş., et al. (2022) · Blood · doi:10.1182/blood.2021013674 · Cited by 44
“Race”, ethnicity and haemoglobin disorders
Dyson, S. M. (1998) · Social Science & Medicine · doi:10.1016/s0277-9536(98)00023-9 · Cited by 44
Rapamycin increases fetal hemoglobin and ameliorates the nociception phenotype in sickle cell mice
Khaibullina, A., Almeida, L. E. F., Wang, L., Kamimura, S., Wong, E. C. C., Nouraie, M. S., Marić, I., Albani, S. H., Finkel, J. C., & Quezado, Z. (2015) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2015.08.001 · Cited by 42
Vichinsky, E. P., Torres, M. D., Minniti, C. P., Barrette, S., Habr, D., Zhang, Y., Files, B. A., & on behalf of the study CICL670A2201 investigators (2013) · American Journal of Hematology · doi:10.1002/ajh.23569 · Cited by 43
Drug Therapies for the Management of Sickle Cell Disease
Rai, P., & Ataga, K. I. (2020) · F1000Research · doi:10.12688/f1000research.22433.1 · Cited by 43
Sickle cell disease: progress towards combination drug therapy
Pace, B. S., Starlard‐Davenport, A., & Kutlar, A. (2021) · British Journal of Haematology · doi:10.1111/bjh.17312 · Cited by 46
“Subsequently, the landmark Multicenter Study of Hydroxycarbamide in Patients with Sickle Cell Anemia (MSH) was completed in 1995 demonstrating the clinical benefit of hydroxycarbamide in producing a decrease in VOC pain episodes in 50% of adult patients.(38,39) Although hydroxycarbamide has disease-modifying effects u…”
BackgroundPsychosocial Treatments in Pain Management of Sickle Cell Disease
Edwards, L., & Edwards, C. L. (2010) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)30737-9 · Cited by 43
Pharmacotherapy in sickle cell disease – state of the art and future prospects
Hankins, J. S., & Aygün, B. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07602.x · Cited by 43
Hankins, J. S., Wynn, L. W., Brugnara, C., Hillery, C. A., Li, C., & Wang, W. C. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06884.x · Cited by 43
Loukopoulos, D., Voskaridou, E., Kalotychou, V., Schina, M., Loutradi, A., & Theodoropoulos, I. (2000) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2000.0328 · Cited by 43
Meo, A., Cassinerio, E., Castelli, R., Bignamini, D., Perego, L., & Cappellini, M. D. (2007) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2007.00965.x · Cited by 43
Hydroxyurea Therapy for Pediatric Patients With Hemoglobin SC Disease
Miller, M. K., Zimmerman, S. A., Schultz, W. H., & Ware, R. E. (2001) · The American journal of pediatric hematology/oncology · doi:10.1097/00043426-200106000-00014 · Cited by 43
Elimination of Transfusions Through Induction of Fetal Hemoglobin Synthesis in Cooley's Anemiaa
Olivieri, N. F., Rees, D. C., Ginder, G. D., Thein, S. L., Waye, J. S., Chang, L., Brittenham, G. M., & Weatherall, D. J. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10467.x · Cited by 43
Evidence gaps in the management of sickle cell disease: A summary of needed research
Savage, W. J., Buchanan, G. R., Yawn, B. P., Afenyi‐Annan, A., Ballas, S. K., Goldsmith, J. C., Hassell, K. L., James, A., John‐Sowah, J., Jordan, L. B., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.23945 · Cited by 43
Crosby, L. E., Barach, I. M., McGrady, M. E., Kalinyak, K. A., Eastin, A. R., & Mitchell, M. J. (2012) · Anemia · doi:10.1155/2012/492428 · Cited by 43
Netzer, G., Liu, X., Shanholtz, C. B., Harris, A. D., Verceles, A. C., & Iwashyna, T. J. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181ffdd2f · Cited by 42
Lactate dehydrogenase in sickle cell disease
Stankovic, K., & Lionnet, F. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.04.035 · Cited by 42
Ataga, K. I., Derebail, V. K., Caughey, M. C., Elsherif, L., Shen, J. H., Jones, S., Maitra, P., Pollock, D. M., Cai, J., Archer, D. R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162652 · Cited by 41
Impact of Chronic Conditions on Emergency Department Visits of Children Using Medicaid
Berry, J. G., Rodean, J., Hall, M., Alpern, E. R., Aronson, P. L., Freedman, S. B., Brousseau, D. C., Shah, S. S., Simon, H. K., Cohen, E., et al. (2016) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.11.054 · Cited by 42
“For children with sickle cell anemia, vaso-occlusive episodes and pain (the leading causes of their ED visits(45)) are known to be reduced with consistent use of hydroxyurea.(46) However, some studies suggest the vast majority of children from lowincome families are not regularly using hydroxyurea.”
BackgroundDisease burden and the role of pharmacogenomics in African populations
Mpye, K., Matimba, A., Dzobo, K., Chirikure, S., Wonkam, A., & Dandara, C. (2017) · Global Health, Epidemiology and Genomics · doi:10.1017/gheg.2016.21 · Cited by 37
“It is effective in increasing total and fetal hemoglobin (HbF), with a consequent reduction in the incidence of acute pain episodes, acute chest syndrome, and hospitalization [88].”
BackgroundBakshi, N., Sinha, C. B., Ross, D. C., Khemani, K., Loewenstein, G. F., & Krishnamurti, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178413 · Cited by 42
NEW THERAPEUTIC OPTIONS FOR THE TREATMENT OF SICKLE CELL DISEASE
Mattè, A., Mazzi, F., Federti, E., Olivieri, O., & Franceschi, L. D. (2019) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2019.002 · Cited by 46
Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease
Adamkiewicz, T. V., Mehta, P., Boyer, M. W., Kedar, A., Olson, T. A., Olson, E. A., Chiang, K., MAURER, D. H., Mogul, M. J., Wingard, J. R., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704606 · Cited by 42
Panepinto, J. A., Hoffmann, R. G., & Pajewski, N. M. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22651 · Cited by 42
Cita, K.-C., Brureau, L., Lemonne, N., Billaud, M., Connes, P., Ferdinand, S., Tressières, B., Tarer, V., Etienne‐Julan, M., Blanchet, P., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154866 · Cited by 42
“hydroxycarbamide), all of which are known to modify the hematological profile of patients with SCA [32, 33].”
BackgroundAtweh, G. F., DeSimone, J., Saunthararajah, Y., Fathallah, H., Weinberg, R. S., Nagel, R. L., Fabry, M. E., & Adams, R. J. (2003) · Hematology · doi:10.1182/asheducation-2003.1.14 · Cited by 42
Jane, S. M., & Cunningham, J. M. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00811.x · Cited by 42
Rediscovering hydroxyurea: its role in recalcitrant psoriasis
Kumar, B., Saraswat, A., & Kaur, I. (2001) · International Journal of Dermatology · doi:10.1046/j.1365-4362.2001.01255.x · Cited by 42
HYDROXYUREA IN THE TREATMENT OF SICKLE CELL ASSOCIATED PRIAPISM
Jama, A., & Dabbous, I. (1998) · The Journal of Urology · doi:10.1097/00005392-199805000-00065 · Cited by 42
Sickle Cell Disease at 100 Years
Orkin, S. H., & Higgs, D. R. (2010) · Science · doi:10.1126/science.1194035 · Cited by 40
Inpatient management of sickle cell pain: A ‘snapshot’ of current practice
Miller, S. T., Kim, H., Weiner, D. L., Wager, C. G., Gallagher, D. M., Styles, L. A., & Dampier, C. (2011) · American Journal of Hematology · doi:10.1002/ajh.22265 · Cited by 41
In vitro and in vivo anti-angiogenic effects of hydroxyurea
Lopes, F. C. M., Ferreira, R., de Albuquerque, D. M., Silveira, A. A. A., Costa, R., Soares, R. A., Costa, F. F., & Conran, N. (2014) · Microvascular Research · doi:10.1016/j.mvr.2014.05.009 · Cited by 41
Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters
Walker, A. L., Franke, R. M., Sparreboom, A., & Ware, R. E. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.01.004 · Cited by 41
Blood bank management of sickle cell patients at comprehensive sickle cell centers
Afenyi‐Annan, A., Willis, M. S., Konrad, T. R., & Lottenberg, R. (2007) · Transfusion · doi:10.1111/j.1537-2995.2007.01434.x · Cited by 41
Cellular normoxic biophysical markers of hydroxyurea treatment in sickle cell disease
Hosseini, P., Abidi, S. Z., Du, E., Papageorgiou, D. P., Choi, Y., Park, Y., Higgins, J. M., Kato, G. J., Suresh, S., Dao, M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610435113 · Cited by 42
Risk Factors for 30-Day Readmission in Adults with Sickle Cell Disease
Brodsky, M. A., Rodeghier, M., Sanger, M., Byrd, J., McClain, B. L., Covert, B. V., Roberts, D. O., Wilkerson, K., DeBaun, M. R., & Kassim, A. A. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.12.010 · Cited by 41
Tian, Y., Liu, G., Wang, H., Tian, Z., Cai, Z., Zhang, F., Luo, Y. Y., Wang, S., Guo, G., Wang, X., et al. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.08.002 · Cited by 41
Emerging therapies in sickle cell disease
Nardo‐Marino, A., Brousse, V. A. M., & Rees, D. C. (2020) · British Journal of Haematology · doi:10.1111/bjh.16504 · Cited by 42
Dugdale, M. (2001) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70206-0 · Cited by 41
Pells, J. J., Presnell, K. E., Edwards, C. L., Wood, M. E., Harrison, M. O., DeCastro, L. M., Johnson, S., Feliu, M., Canada, S. A., Jonassaint, J., et al. (2005) · PubMed Central · Cited by 41
History of Pediatric Hematology Oncology
Pearson, H. A. (2002) · Pediatric Research · doi:10.1203/00006450-200212000-00026 · Cited by 41
Lee, K., Gane, P., Roudot‐Thoraval, F., Godeau, B., Bachir, D., Bernaudin, F., Cartron, J., Galactéros, F., & Bierling, P. (2001) · Blood · doi:10.1182/blood.v98.4.966 · Cited by 41
Mechanism for fetal hemoglobin induction by hydroxyurea in sickle cell erythroid progenitors
Baliga, B. S., Pace, B. S., Chen, H.-H., Shah, A. K., & Yang, Y. (2000) · American Journal of Hematology · doi:10.1002/1096-8652(200011)65:3 · Cited by 41
Fetal hemoglobin in sickle cell anemia: relationship to erythrocyte adhesion markers and adhesion
Setty, Y. B. N., Kulkarni, S., Dampier, C., & Stuart, M. J. (2001) · Blood · doi:10.1182/blood.v97.9.2568 · Cited by 41
Sickle Cell Anemia: Targeting the Role of Fetal Hemoglobin in Therapy
Coleman, E., & Inusa, B. P. D. (2007) · Clinical Pediatrics · doi:10.1177/0009922806297751 · Cited by 40
Ofakunrin, A. O. D., Oguche, S., Adekola, K., Okpe, E. S., Afolaranmi, T., Diaku-Akinwumi, I., Zoakah, A., & Sagay, A. S. (2019) · Journal of Tropical Pediatrics · doi:10.1093/tropej/fmz070 · Cited by 41
Karki, N. R., & Kutlar, A. (2021) · Journal of Pain Research · doi:10.2147/jpr.s278285 · Cited by 43
Efficacy of niprisan in the prophylactic management of patients with sickle cell disease
Wambebe, C. O., Bamgboye, E. A., Badru, B. O., Khamofu, H., Momoh, J. A., Ekpeyong, M., Audu, B. S., Njoku, S. O., Nasipuri, N. R., Kunle, O. O., et al. (2001) · Current Therapeutic Research · doi:10.1016/s0011-393x(01)80039-4 · Cited by 40
Brandow, A. M., Brousseau, D. C., & Panepinto, J. A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07512.x · Cited by 40
Prevention and Management of Stroke in Sickle Cell Anemia
Platt, O. S. (2006) · Hematology · doi:10.1182/asheducation-2006.1.54 · Cited by 40
Avascular Necrosis of the Femoral Head in Adult Kuwaiti Sickle Cell Disease Patients
Marouf, R., Gupta, R., Haider, M. Z., Wazzan, H. A., & Adekile, A. D. (2003) · Acta Haematologica · doi:10.1159/000072406 · Cited by 40
New Uses for Old Drugs in HIV Infection
Ravot, E., Lisziewicz, J., & Lori, F. (1999) · Drugs · doi:10.2165/00003495-199958060-00001 · Cited by 40
The Current Role of Hydroxyurea in the Treatment of Sickle Cell Anemia
Rubio, M. L., & Marina, M. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216404 · Cited by 44
“Despite advances in treatment, hydroxyurea (HU) remains the primary therapy since its pivotal trial in 1995, which showed a reduction in vaso-occlusive crises (VOCs) and blood transfusions [5].”
BackgroundTargeted Fetal Hemoglobin Induction for Treatment of Beta Hemoglobinopathies
Perrine, S. P., Pace, B. S., & Faller, D. V. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.11.009 · Cited by 39
Okam, M. M., Shaykevich, S., Ebert, B. L., Zaslavsky, A. M., & Ayanian, J. Z. (2014) · Medical Care · doi:10.1097/mlr.0000000000000143 · Cited by 39
“11 Children (< 18) 19,850 (27) 14,803 (21) < 5 4760 (6) 3493 (5) < 0.”
Marahatta, A., Megaraj, V., McGann, P. T., Ware, R. E., & Setchell, K. D. R. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.263715 · Cited by 39
Accelerating the Drug Delivery Pipeline for Acute and Chronic Pancreatitis
Abu‐El‐Haija, M. A., Gukovskaya, A. S., Andersen, D. K., Gardner, T. B., Hegyi, P. J., Pandol, S. J., Papachristou, G. I., Saluja, A. K., Singh, V. K., Uç, A., et al. (2018) · Pancreas · doi:10.1097/mpa.0000000000001175 · Cited by 38
Guilliams, K. P., Fields, M. E., & Dowling, M. M. (2019) · Stroke · doi:10.1161/strokeaha.118.020482 · Cited by 39
Farrell, A. T., Panepinto, J. A., Desai, A. A., Kassim, A. A., Lebensburger, J. D., Walters, M. C., Bauer, D. E., Blaylark, R. M., DiMichele, D., Gladwin, M. T., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000883 · Cited by 41
Metadata
- Authors
- Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R.
- Affiliations
- Johns Hopkins University (US)
- Maryland Medical Research Institute (US)
- National Heart, Lung, and Blood Institute (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1995-05-18
- Volume
- 332
- Issue
- 20
- Pages
- 1317-1322
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2313541759
- Semantic Scholar
- 2c0939e2f6480b519903bb15870e5b894887e70d
- Cited by
- 2,340
- References
- 26
- Citations by year
- 2026: 67 · 2025: 97 · 2024: 77 · 2023: 88 · 2022: 95 · 2021: 92 · 2020: 80 · 2019: 78 · 2018: 85 · 2017: 104 · 2016: 114 · 2015: 101 · 2014: 82 · 2013: 79 · 2012: 73
- FWCI
- 34.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- National Institutes of Health (5u01hl045696-05)
- National Heart, Lung, and Blood Institute (UO1-HL 45696, UO1 HL 45692, U01HL045692)
- National Center for Research Resources (RR00046, M01RR000046)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Keywords
- hydroxyurea, sickle cell disease, vaso-occlusive crisis, fetal hemoglobin, blood transfusion, myelosuppression, treatment efficacy, adverse effects
- MeSH terms
- Adult, Anemia, Sickle Cell, Double-Blind Method, Female, Follow-Up Studies, Humans, Hydroxyurea, Male, Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
